💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Asciminib

CHEMBL4208229 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
449.8 g/mol
LogP
3.0
Phase
4

A BCR-ABL1 inhibitor that uniquely targets the myristoyl pocket of the ABL1 enzyme rather than the ATP-binding site, overcoming many resistance mutations that limit other leukemia drugs. It is approved for chronic myeloid leukemia, including in patients with the T315I mutation.

Khối lượng phân tử

449,8000 g/mol

LogP

3,00

TPSA

103,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Breast Cancer Leukemia

Cơ chế tác dụng

Inhibits the BCR-ABL fusion tyrosine kinase, the constitutively active oncoprotein responsible for driving chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits the BCR-ABL fusion tyrosine kinase, the constitutively active oncoprotein responsible for driving chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H18ClF2N5O3

                    

                    
                    

                        
HBD / HBA

                        
3 / 8

                    

                    
                    

                        
Liên kết có thể quay

                        
6

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
31

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
A BCR-ABL1 inhibitor that uniquely targets the myristoyl pocket of the ABL1 enzyme rather than the ATP-binding site, overcoming many resistance mutations that limit other leukemia drugs. It is approved for chronic myeloid leukemia, including in patients with the T315I mutation.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits the BCR-ABL fusion tyrosine kinase, the constitutively active oncoprotein responsible for driving chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Asciminib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4208229.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 72165228.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.